Evogene Resolves Board Dispute with Pure Capital Group…

Event summary

Evogene and Pure Capital Group reached a cooperation agreement on October 6, 2026, to resolve all outstanding differences and reconstitute the board of directors.
Two current directors, Dr. Yael Margolin and Mr. Yoshinori Oikawa, will be replaced by Pure Capital Group nominees Dr. Adi Zuluf-Shani and Mr. Oz Adler.
A general meeting of shareholders will be convened within 42 days to elect the new directors and approve the agreement.
The reconstituted board will comprise seven directors, including four nominated by the Pure Capital Group and three continuing directors serving a transition period of up to six months.
Pure Capital Group has agreed to withdraw its notice regarding a special tender offer and enter into a 60-day standstill period.

The big picture

The agreement between Evogene and Pure Capital Group aims to establish long-term operational stability, allowing Evogene to focus on its goal of becoming a world leader in AI-driven small-molecule discovery. This resolution avoids a prolonged legal process and ensures that Evogene can continue advancing its technology development centered on ChemPass AI™. The reconstitution of the board reflects a strategic shift in governance, potentially influencing the company's future direction and market positioning.

What we're watching

Governance Dynamics: How the new board composition will affect Evogene's strategic direction and operational stability.
Execution Risk: Whether the transition period and potential removal of continuing directors will create short-term disruptions.
Market Stability: The pace at which Evogene can advance its business strategy and commercial collaborations following the resolution.